Targeting a host process as an antiviral approach against dengue virus.
The re-emergence of dengue virus as a significant human pathogen has lead to an increasing need for effective antivirals. Development of therapeutic agents with the ability to attenuate both the duration and severity of disease in patients after infection is particularly desirable in dengue endemic resource-poor settings. The reliance of dengue virus on endogenous processes during the late stages of infection prompts the development of molecules to interfere with and exploit these dependencies as potential antiviral therapies. Here we focus on the importance of N-linked glycan processing in infectious virion morphogenesis.
Sayce
Andrew C
AC
Department of Genetics and Biochemistry, Clemson University, 217 Biosystems Research Complex, 51 New Cherry Street, Clemson, SC 29634, USA.
Miller
Joanna L
JL
Zitzmann
Nicole
N
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D006224:Cricetinae; D003715:Dengue / Q000188:drug therapy; D003716:Dengue Virus / Q000378:metabolism* / Q000472:pathogenicity*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006031:Glycosylation; D054884:Host-Pathogen Interactions; D006801:Humans; D020128:Inhibitory Concentration 50; D008954:Models, Biological; D011499:Protein Processing, Post-Translational; D014764:Viral Proteins / Q000378:metabolism*
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D014764:Viral Proteins